Randomized phase II-III study of matrix metalloproteinase inhibitor (MMPI) BMS-275291 in combination with paclitaxel (P) and carboplatin (C) in advanced non-small cell lung cancer (NSCLC): NCIC-CTG BR. 18.

被引：0
|
作者：
Leighl, NB
Shepherd, F
Paz-Ares, L
Douillard, JY
Peschel, C
Arnold, A
Tu, D
Galbraith, S
Hann, K
Seymour, L
机构：
[1] Natl Canc Inst Canada, Kingston, ON, Canada
[2] Bristol Myers Squibb, Wallingford, CT USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7038
引用
收藏
页码：626S / 626S
页数：1
相关论文
共 50 条
  • [31] COMPARATIVE EFFICACY AND SAFETY OF ERLOTINIB IN NON-SMALL CELL LUNG CANCER (NSCLC) OF SQUAMOUS CELL AND ADENOCARCINOMA HISTOLOGY IN THE PHASE III NCIC CTG BR. 21 AND SATURN (BO18192) TRIALS
    Wojtowicz-Praga, S.
    Leon, L.
    ANNALS OF ONCOLOGY, 2012, 23 : 419 - 419
  • [32] A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab with or without Concurrent Cetuximab in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): SWOG S0819
    Herbst, Roy
    Redman, Mary
    Kim, Edward S.
    Semrad, Thomas J.
    Bazhenova, Lyudmila
    Masters, Gregory
    Oettel, Kurt
    Guaglianone, Perry
    Reynolds, Christopher
    Karnad, Anand
    Arnold, Susanne M.
    Varella-Garcia, Marileila
    Moon, James
    Mack, Philip C.
    Blanke, Charles D.
    Hirsch, Fred R.
    Gandara, David R.
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S795 - S795
  • [33] A phase II study of Endostatin in combination with paclitaxel, carboplatin, and radiotherapy in patients with unresectable locally advanced non-small cell lung cancer
    Sun, Xiao-Jiang
    Deng, Qing-Hua
    Yu, Xin-Min
    Ji, Yong-Lin
    Zheng, Yuan-Da
    Jiang, Hao
    Xu, Ya-Ping
    Ma, Sheng-Lin
    BMC CANCER, 2016, 16
  • [34] Phase II study of low dose suramin as a sensitizer of paclitaxel/carboplatin (P/C) in non small cell lung cancer (NSCLC).
    Villalona-Calero, MA
    Otterson, GA
    Wientjes, G
    Kobayashi, K
    Jensen, R
    Young, D
    Yeh, T
    Song, S
    Grever, M
    Au, J
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 643S - 643S
  • [35] A phase II study of Endostatin in combination with paclitaxel, carboplatin, and radiotherapy in patients with unresectable locally advanced non-small cell lung cancer
    Xiao-Jiang Sun
    Qing-Hua Deng
    Xin-Min Yu
    Yong-Lin Ji
    Yuan-Da Zheng
    Hao Jiang
    Ya-Ping Xu
    Sheng-Lin Ma
    BMC Cancer, 16
  • [36] Randomized, double-blind phase II/III study of first-line paclitaxel (P) plus carboplatin (C) in combination with vorinostat or placebo in patients with advanced non-small-cell lung cancer (NSCLC)
    Belani, C.
    Ramalingam, S.
    Kalemkerian, G.
    Mok, T.
    Rosell, R.
    Ahn, M. J.
    Sun, L.
    Gates, M.
    Lubiniecki, G. M.
    Govindan, R.
    EJC SUPPLEMENTS, 2009, 7 (02): : 507 - 507
  • [37] Phase II randomized, open-label study of cetuximab (Cet) and bevacizumab (Bev) in combination with paclitaxel (P) and carboplatin (C) in patients with stageIII/IV non-small cell lung cancer (NSCLC)
    Bonomi, P. D.
    Mace, J.
    Mandanas, R. D.
    Min, M.
    Zhang, Y.
    Rowinsky, E.
    Youssoufian, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [38] A RANDOMIZED, PHASE 2 STUDY OF PACLITAXEL (P) AND CARBOPLATIN (C) ± CONATUMUMAB (CON) FOR FIRST-LINE TREATMENT OF NON-SMALL CELL LUNG CANCER (NSCLC)
    Paz-Ares, L.
    Balint, B.
    de Boer, R.
    van Meerbeeck, J. P.
    Wierzbicki, R.
    Desouza, P. L.
    Galimi, F.
    Haddad, V.
    Hei, Y.
    Ramlau, R.
    ANNALS OF ONCOLOGY, 2010, 21 : 137 - 137
  • [39] Prospective correlative assessment of biomarkers in E4599 randomized phase II/III trial of carboplatin and paclitaxel ± bevacizumab in advanced non-small cell lung cancer (NSCLC).
    Dowlati, A.
    Gray, R.
    Johnson, D. H.
    Schiller, J. H.
    Brahmer, J.
    Sandler, A. B.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 370S - 370S
  • [40] Phase I dose-escalation study of sorafenib in combination with bevacizumab (B), paclitaxel (P), and carboplatin (C) for the treatment of advanced nonsquamous non-small cell lung cancer (NSCLC).
    Blumenschein, G. R.
    Molina, J. R.
    Lathia, C. D.
    Ong, T. J.
    Roth, D.
    Rajagopalan, P.
    Fossella, F. V.
    Kies, M. S.
    Marks, R. S.
    Adjei, A. A.
    Sundaresan, P. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345